Linda B. Baughn, Ph.D.

  1. Clinical Cytogeneticist
  2. Clinical Molecular Geneticist
  1. Essiaw LA, Bolarinwa A, Tang H, Kudowor G, Shivaram S, Sharma N, Linden MA, Buadi FK, Rajkumar SV, Kumar S, Dei-Adomakoh Y, Cook JM, Baughn LB, Paemka L. Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients. Clin Lymphoma Myeloma Leuk 2024 Dec; 24 (12):863-868 Epub 2024 July 17
    View PubMed
  2. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Bennett SA, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Kourelis T, Muchtar E, Zhou J, Rajkumar SV, Kumar SK, Olteanu H. FDA IDE validation of multiple myeloma MRD test by flow cytometry. Am J Hematol 2024 Dec; 99 (12):2399-2401 Epub 2024 Sept 18
    View PubMed
  3. Tang H, Yan H, Shivaram S, Lehman S, Sharma N, Smadbeck J, Zepeda-Mendoza C, Tian S, Asmann Y, Vachon C, Gaspar Maia A, Keats J, Bergsagel PL, Fonseca R, Stewart AK, Hsu JS, Kandasamy RK, Pandey A, Kaddoura MA, Maura F, Mitra A, Rajkumar SV, Kumar SK, Elhaik E, Braggio E, Baughn LB. Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). Leukemia. 2024 Oct 14 [Epub ahead of print]
    View PubMed
  4. Gao RW, Fleuranvil RF, Harmsen WS, Tao R, Pulsipher SD, Greipp PT, Baughn LB, Jevremovic D, Gonsalves WI, Kourelis TV, Stish BJ, Peterson JL, Rule WG, Hoppe BS, Breen WG, Lester SC. Predictors of Local Control With Palliative Radiotherapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Oct 5 Epub 2024 Oct 05
    View PubMed
  5. Gagnon MF, Meyer RG, Weaver EJ, Wood AJ, Dupuy DA Jr, Menachery SJ, Shi M, Baughn LB, Ketterling RP, Peterson JF. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements. Lab Med. 2024 Sep 4; 55 (5):649-654
    View PubMed
  6. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, Kumar S. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 2024 Aug; 38 (8):1865
    View PubMed
  7. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Zhou J, Dispenzieri A, Kourelis T, Muchtar E, Rajkumar SV, Kumar SK, Olteanu H. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. Blood Cancer J 2024 Jul 31; 14 (1):126 Epub 2024 July 31
    View PubMed
  8. Gagnon MF, Bruehl FK, Sill DR, Meyer RG, Greipp PT, Hoppman NL, Xu X, Baughn LB, Peterson JF, McPhail ED, Ketterling RP, King RL. Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients. J Hematop. 2024 Jun; 17 (2):51-61 Epub 2024 Apr 02
    View PubMed
  9. Akkari Y, Baughn LB, Kim A, Karaca E, Raca G, Shao L, Mikhail FM, ACMG Laboratory Quality Assurance Committee. Electronic address: documents@acmg.net. Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes. Genet Med. 2024 Apr; 26 (4):101054 Epub 2024 Feb 13
    View PubMed
  10. Gagnon MF, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, Meyer RG, Ailawadhi S, Arribas MJ, Braggio E, Fonseca R, Rajkumar SV, Zepeda-Mendoza C, Xu X, Greipp PT, Timm MM, Otteson GE, Shi M, Jevremovic D, Olteanu H, Peterson JF, Ketterling RP, Kumar S, Baughn LB. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024 Jan 4; 161 (1):60-70
    View PubMed
  11. Gagnon MF, Penheiter AR, Harris F, Sadeghian D, Johnson SH, Karagouga G, McCune A, Zepeda-Mendoza C, Greipp PT, Xu X, Ketterling RP, McPhail ED, King RL, Peterson JF, Vasmatzis G, Baughn LB. Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis. Blood Cancer J 2023 Dec 19; 13 (1):190
    View PubMed
  12. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  13. Pitel BA, Zepeda-Mendoza C, Sachs Z, Tang H, Shivaram S, Sharma N, Smadbeck JB, Smoley SA, Pearce KE, Luoma IM, Cook J, Litzow MR, Hoppman NL, Viswanatha D, Xu X, Ketterling RP, Greipp PT, Peterson JF, Baughn LB. Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia. Blood Cancer J 2023 Sep 6; 13 (1):138 Epub 2023 Sept 06
    View PubMed
  14. Baughn LB, Jessen E, Sharma N, Tang H, Smadbeck JB, Long MD, Pearce K, Smith M, Dasari S, Sachs Z, Linden MA, Cook J, Keith Stewart A, Chesi M, Mitra A, Leif Bergsagel P, Van Ness B, Kumar SK. Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma. Blood Cancer J. 2023 May 22; 13 (1):84
    View PubMed
  15. Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J. 2023 May 15; 13 (1):78
    View PubMed
  16. Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, Otteson GE, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Rajkumar SV, Kumar SK, Jevremovic D. Utility of flow cytometry screening before MRD testing in multiple myeloma. Blood Cancer J 2023 Apr 20; 13 (1):55
    View PubMed
  17. Levy B, Baughn LB, Akkari Y, Chartrand S, LaBarge B, Claxton D, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Adv. 2023 Apr 11; 7 (7):1297-1307
    View PubMed
  18. Venable ER, Gagnon MF, Pitel BA, Palmer JM, Peterson JF, Baughn LB, Hoppman NL, Greipp PT, Ketterling RP, Patnaik MS, Kelemen K, Xu X. A TRIP11:: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature. Cold Spring Harb Mol Case Stud. 2023 Feb; 9 (1) Epub 2023 Mar 24
    View PubMed
  19. Choate LA, Jiang L, Stein MI, Shen W, Baughn LB, Peterson JF. Detection of an MN1::ETV6 Gene Fusion in a Case of Acute Myeloid Leukemia with Erythroid Differentiation: A Case Report and Review of the Literature. Case Rep Hematol. 2023; 2023:9771388 Epub 2023 July 03
    View PubMed
  20. Koleilat A, Tang H, Sharma N, Yan H, Tian S, Smadbeck J, Shivaram S, Meyer R, Pearce K, Baird M, Zepeda-Mendoza CJ, Xu X, Greipp PT, Peterson JF, Ketterling RP, Bergsagel PL, Vachon C, Rajkumar SV, Kumar S, Asmann YW, Elhaik E, Baughn LB. Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm. Genet Med Open. 2023; 1 (1):100816 Epub 2023 May 09
    View PubMed
  21. Koleilat A, Smadbeck JB, Zepeda-Mendoza CJ, Williamson CM, Pitel BA, Golden CL, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Peterson JF, Harrison CJ, Akkari YMN, Tsuchiya KD, Shago M, Baughn LB. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes Cancer. 2022 Dec; 61 (12):710-719 Epub 2022 July 19
    View PubMed
  22. Gagnon MF, Berg HE, Meyer RG, Sukov WR, Van Dyke DL, Jenkins RB, Greipp PT, Thorland EC, Hoppman NL, Xu X, Baughn LB, Reichard KK, Ketterling RP, Peterson JF. Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studies. Genes Chromosomes Cancer. 2022 Oct; 61 (10):629-634 Epub 2022 June 10
    View PubMed
  23. Dalland JC, Blackburn PR, Reichard KK, Johnson SH, Smadbeck JB, Vasmatzis G, Hoppman NL, Xu X, Greipp PT, Baughn LB, Peterson JF. A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. Lab Med. 2022 Sep 1; 53 (5):e134-e138
    View PubMed
  24. Gagnon MF, Smadbeck JB, Sharma N, Blackburn PR, Demasi Benevides J, Akkari YMN, Jaroscak JJ, Znoyko I, Wolff DJ, Schandl CA, Meyer R, Greipp PT, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Baughn LB. Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leuk Lymphoma 2022 Sep; 63 (9):2243-2246 Epub 2022 May 04
    View PubMed
  25. Gagnon MF, Tian S, Geyer S, Sharma N, Vachon CM, Kusne Y, Bergsagel PL, Stewart AK, Rajkumar SV, Kumar S, Ailawadhi S, Baughn LB. Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms. Blood Cancer J 2022 Jul 26; 12 (7):112 Epub 2022 July 26
    View PubMed
  26. Macke EL, Meyer RG, Hoppman NL, Ketterling RP, Greipp PT, Xu X, Baughn LB, Shafer DA, He RR, Peterson JF. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia. Lab Med. 2022 Jul 4; 53 (4):e87-e90
    View PubMed
  27. Berg HE, Greipp PT, Baughn LB, Falcon CP, Jackson CC, Peterson JF. Detection of a Cryptic KMT2A/AFDN Gene Fusion [ins(6;11)(q27;q23q23)] in a Pediatric Patient with Newly Diagnosed Acute Myeloid Leukemia. Lab Med. 2022 Jul 4; 53 (4):e95-e99
    View PubMed
  28. Gagnon MF, Smadbeck JB, Vasmatzis G, Olteanu H, Wood AJ, Lewis DJ, Sharma N, Meyer RG, Greipp PT, Xu X, Hoppman NL, Baughn LB, Ketterling RP, Chiu A, Peterson JF. Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature. Ann Diagn Pathol. 2022 Jun; 58:151942 Epub 2022 Mar 23
    View PubMed
  29. Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Res. 2022 Apr 15; 82 (8):1448-1460
    View PubMed
  30. Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, Haase DT, Schlegelberger B, Slavutsky I, Mecucci C, Levine RL, Hasserjian RP, Sole F, Levy B, Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022 Apr 14; 139 (15):2273-2284
    View PubMed
  31. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, Kumar S. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 2022 Apr; 36 (4):1058-1065 Epub 2021 Nov 11
    View PubMed
  32. Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, Baughn LB, Van Ness BG, Mitra AK. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer J. 2022 Mar 9; 12 (3):39 Epub 2022 Mar 09
    View PubMed
  33. Abdel Rahman ZH, Parrondo RD, Heckman MG, Wieczorek M, Miller KC, Alkhateeb H, Sproat LZ, Murthy H, Hogan WJ, Kharfan-Dabaja MA, Peterson JF, Baughn LB, Hoppman N, Litzow MR, Ketterling RP, Greipp PT, Foran JM. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 Feb; 196 (4):963-968 Epub 2021 Oct 25
    View PubMed
  34. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022 Jan 31; 12 (1):21
    View PubMed
  35. Koleilat A, McGarrah PW, Olteanu H, Van Dyke DL, Smadbeck JB, Johnson SH, Vasmatzis G, Hoppman NL, Xu X, Ketterling RP, Greipp PT, Baughn LB, Patnaik MS, Peterson JF. Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genet. 2022 Jan; 260-261:1-5 Epub 2021 Nov 06
    View PubMed
  36. Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WI, Hwa YL, Leung N, Lin Y, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV, Kumar SK. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2022 Jan 1; 97 (1):52-59 Epub 2021 Nov 03
    View PubMed
  37. Kumar H, Mazumder S, Sharma N, Chakravarti S, Long MD, Meurice N, Petit J, Liu S, Chesi M, Sanyal S, Stewart AK, Kumar S, Bergsagel L, Rajkumar SV, Baughn LB, Van Ness BG, Mitra AK. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Front Oncol. 2022; 12:842200 Epub 2022 May 11
    View PubMed
  38. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Baughn LB, Kyle RA, Kumar S. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021 Nov 26; 11 (11):186
    View PubMed
  39. Gagnon MF, Pearce KE, Greipp PT, Xu X, Hoppman NL, Ketterling RP, McPhail ED, King RL, Baughn LB, Peterson JF. MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer J 2021 Nov 24; 11 (11):184
    View PubMed
  40. Dalland JC, Smadbeck JB, Sharma N, Meyer RG, Pearce KE, Greipp PT, Peterson JF, Kumar S, Ketterling RP, King RL, Baughn LB. Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes Cancer. 2021 Oct; 60 (10):678-686 Epub 2021 June 22
    View PubMed
  41. Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, Asmann YW, Peterson JF, Ketterling RP, Greipp PT, Bergsagel PL, Rajkumar SV, Kumar SK, Baughn LB. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clin Cancer Res. 2021 Oct 1; 27 (19):5430-5439
    View PubMed
  42. Abdel-Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, Kharfan-Dabaja MA, Ketterling RP, Litzow MR, Baughn LB, Patnaik M, Greipp PT, Foran JM. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. Blood Cancer J 2021 Sep 21; 11 (9):156 Epub 2021 Sept 21
    View PubMed
  43. Chen JA, Hou Y, Roskin KM, Arber DA, Bangs CD, Baughn LB, Cherry AM, Ewalt MD, Fire AZ, Fresard L, Kearney HM, Montgomery SB, Ohgami RS, Pearce KE, Pitel BA, Merker JD, Gotlib J. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 Sep 14; 5 (17):3492-3496
    View PubMed
  44. Ravindran A, Greipp PT, Wongchaowart N, Smadbeck JB, Peterson JF, Ketterling RP, Kumar SK, Baughn LB. Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clin Lymphoma Myeloma Leuk. 2021 Sep; 21 (9):e710-e713 Epub 2021 May 09
    View PubMed
  45. Guenzel AJ, Smadbeck JB, Golden CL, Williamson CM, Benevides Demasi JC, Vasmatzis G, Pearce KE, Olteanu H, Xu X, Hoppman NL, Greipp PT, Baughn LB, Ketterling RP, Peterson JF. Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. Ann Diagn Pathol. 2021 Aug; 53:151761 Epub 2021 May 10
    View PubMed
  46. Duan Z, Baughn LB, Wang X, Zhang Y, Gupta V, MacCarthy T, Scharff MD, Yu G. Role of Dot1L and H3K79 methylation in regulating somatic hypermutation of immunoglobulin genes. Proc Natl Acad Sci U S A. 2021 Jul 20; 118 (29)
    View PubMed
  47. Han SY, Mrozek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Moller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25; 5 (10):2481-2489
    View PubMed
  48. Berg HE, Blackburn PR, Smadbeck JB, Swanson KE, Rice CS, Webley MR, Johnson SH, Vasmatzis G, Xu X, Greipp PT, Hoppman NL, Ketterling RP, Baughn LB, Boston CH, Sutton LM, Peterson JF. Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia. Lab Med. 2021 May 4; 52 (3):297-302
    View PubMed
  49. Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, Xiao S, Jenkins RB, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Greipp PT, Baughn LB. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J. 2021 Feb 8; 11(2):18.
    View PubMed
  50. Pitel BA, Sharma N, Zepeda-Mendoza C, Smadbeck JB, Pearce KE, Cook JM, Vasmatzis G, Sachs Z, Kanagal-Shamanna R, Viswanatha D, Xiao S, Jenkins RB, Xu X, Hoppman NL, Ketterling RP, Peterson JF, Greipp PT, Baughn LB. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J 2021 Feb 8; 11 (2):18 Epub 2021 Feb 08
    View PubMed
  51. Johannsen EB, Baughn LB, Sharma N, Zjacic N, Pirooznia M, Elhaik E. The Genetics of Sudden Infant Death Syndrome-Towards a Gene Reference Resource. Genes (Basel). 2021 Feb 2; 12 (2) Epub 2021 Feb 02
    View PubMed
  52. Berg HE, Blackburn PR, Baughn LB, Ketterling RP, Xu X, Greipp PT, Hoppman NL, Smadbeck JB, Vasmatzis G, Shi M, Reichard KK, Viswanatha DS, Jevremovic D, Maher GM, Peterson JF. Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. Genes Chromosomes Cancer. 2021 Feb; 60 (2):108-111 Epub 2020 Oct 21
    View PubMed
  53. Zepeda-Mendoza CJ, Essendrup A, Smoley SA, Johnson SH, Hoppman NL, Vasmatzis G, Jackson DL, Kearney HM, Baughn LB. Prenatal characterization of a novel inverted SMAD2 duplication by mate pair sequencing in a fetus with dextrocardia. Clin Case Rep. 2021 Feb; 9 (2):769-774 Epub 2020 Dec 10
    View PubMed
  54. Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Moller M, Schiefer AI, Mrozek K, Horny HP, George TI, Kielsgaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, Litzow MR, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol 2021 Feb; 43 (1):e19-e25 Epub 2020 Sept 14
    View PubMed
  55. Kaya EA, Baughn LB, Pham T, Ketterling RP, Kumar SK, Jevremovic D. Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma. Leuk Lymphoma 2021 Jan; 62 (1):243-246 Epub 2020 Sept 21
    View PubMed
  56. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02
    View PubMed
  57. Marcou CA, Pitel B, Hagen CE, Boczek NJ, Rowsey RA, Baughn LB, Hoppman NL, Thorland EC, Kearney HM. Limited diagnostic impact of duplications <1 Mb of uncertain clinical significance: a 10-year retrospective analysis of reporting practices at the Mayo Clinic. Genet Med. 2020 Dec; 22 (12):2120-2124 Epub 2020 Aug 21
    View PubMed
  58. Martig DS, Williamson CM, Xu X, Sukov WR, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF. Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. Ann Diagn Pathol. 2020 Oct; 48:151588 Epub 2020 Aug 14
    View PubMed
  59. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020 Sep; 95 (9):1989-1999 Epub 2020 July 19
    View PubMed
  60. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020 Aug 11; 4 (15):3509-3519
    View PubMed
  61. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020 Aug 11; 10 (8):82
    View PubMed
  62. Snider JS, Znoyko I, Lindsey KG, Morse J, Baughn LB, Hoppman NL, Pitel BA, Pearce KE, Schandl CA, Wolff DJ. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet. 2020 Aug; 246-247:44-47 Epub 2020 Aug 07
    View PubMed
  63. Mitra AK, Kumar H, Ramakrishnan V, Chen L, Baughn L, Kumar S, Rajkumar SV, Van Ness BG. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. Blood Cancer J. 2020 Jul 28; 10 (7):78 Epub 2020 July 28
    View PubMed
  64. Blackburn PR, Smadbeck JB, Znoyko I, Webley MR, Pitel BA, Vasmatzis G, Xu X, Greipp PT, Hoppman NL, Ketterling RP, Baughn LB, Lindsey KG, Schandl CA, Wolff DJ, Peterson JF. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes Cancer. 2020 Jul; 59 (7):422-427 Epub 2020 Mar 26
    View PubMed
  65. Polonis K, Schultz MJ, Olteanu H, Smadbeck JB, Johnson SH, Vasmatzis G, Xu X, Greipp PT, Ketterling RP, Hoppman NL, Baughn LB, Peterson JF. Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Ann Diagn Pathol. 2020 Jun; 46:151533 Epub 2020 May 06
    View PubMed
  66. Xiao AW, Jia Y, Baughn LB, Pearce KE, Pitel BA, Aster JC, Dal Cin P, Xiao S. IGH rearrangement in myeloid neoplasms. Haematologica 2020 Jun; 105 (6):e315-e317 Epub 2020 Mar 12
    View PubMed
  67. Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020 May 26; 4 (10):2236-2244
    View PubMed
  68. Akkari YMN, Bruyere H, Hagelstrom RT, Kanagal-Shamanna R, Liu J, Luo M, Mikhail FM, Pitel BA, Raca G, Shago M, Shao L, Smith LR, Smolarek TA, Yenamandra A, Baughn LB. Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genet. 2020 May; 243:52-72 Epub 2020 Mar 21
    View PubMed
  69. Lopes JL, Webley M, Pitel BA, Pearce KE, Smadbeck JB, Johnson SH, Vasmatzis G, Sukov WR, Greipp PT, Hoppman NL, Ketterling RP, Baughn LB, Finn L, Peterson JF. Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. Cancer Genet. 2020 May; 243:48-51 Epub 2020 Mar 17
    View PubMed
  70. Schultz MJ, Blackburn PR, Cogbill CH, Pitel BA, Smadbeck JB, Johnson SH, Vasmatzis G, Rech KL, Sukov WR, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF. Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. Leuk Lymphoma 2020 Apr; 61 (4):975-978 Epub 2019 Dec 06
    View PubMed
  71. Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM. Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. Am J Hematol 2020 Mar; 95 (3):E68-E72 Epub 2020 Jan 26
    View PubMed
  72. Blackburn PR, Huang L, Dalovisio A, Pitel BA, Chen D, Oliveira JL, Wood AJ, Smadbeck JB, Johnson SH, Vasmatzis G, Haferlach C, Greipp PT, Hoppman NL, Ketterling RP, Baughn LB, Peterson JF. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. Cancer Genet 2020 Feb; 241:67-71 Epub 2019 Dec 26
    View PubMed
  73. Peterson JF, Pearce KE, Meyer RG, Greipp PT, Knudson RA, Baughn LB, Ketterling RP, Feldman AL. Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. Histopathology. 2020 Feb; 76 (3):481-485 Epub 2020 Jan 17
    View PubMed
  74. Smadbeck J, Peterson JF, Pearce KE, Pitel BA, Figueroa AL, Timm M, Jevremovic D, Shi M, Stewart AK, Braggio E, Riggs DL, Bergsagel PL, Vasmatzis G, Kearney HM, Hoppman NL, Ketterling RP, Kumar S, Rajkumar SV, Greipp PT, Baughn LB. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer J. 2019 Dec 16; 9 (12):103
    View PubMed
  75. Zepeda-Mendoza CJ, Cousin MA, Basu S, Jenkinson G, Oliver G, Pittock ST, Baughn LB, Klee EW, Babovic-Vuksanovic D. An intragenic duplication of TRPS1 leading to abnormal transcripts and causing trichorhinophalangeal syndrome type I. Cold Spring Harb Mol Case Stud. 2019 Dec; 5 (6) Epub 2019 Dec 13
    View PubMed
  76. Rowsey RA, Smoley SA, Williamson CM, Vasmatzis G, Smadbeck JB, Ning Y, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF. Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. Blood Cancer J. 2019 Oct 1; 9 (10):81 Epub 2019 Oct 01
    View PubMed
  77. Peterson JF, Ketterling RP, Huang L, Finn LE, Shi M, Hoppman NL, Greipp PT, Baughn LB. A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia. Genes Chromosomes Cancer. 2019 Sep; 58 (9):665-668 Epub 2019 Mar 18
    View PubMed
  78. Peterson JF, He RR, Nayer H, Cuevo RS, Smadbeck JB, Vasmatzis G, Greipp PT, Ketterling RP, Hoppman NL, Baughn LB. Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genet. 2019 Sep; 237:51-54 Epub 2019 June 12
    View PubMed
  79. Peterson JF, Meyer RG, Smoley SA, Webley M, Smadbeck JB, Vasmatzis G, Pearce K, Greipp PT, Ketterling RP, Craig FE, Stewart AK, Baughn LB. Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. Clin Lymphoma Myeloma Leuk. 2019 Sep; 19 (9):598-602 Epub 2019 June 18
    View PubMed
  80. Peterson JF, Sukov WR, Pitel BA, Smoley SA, Pearce KE, Meyer RG, Williamson CM, Smadbeck JB, Vasmatzis G, Hoppman NL, Greipp PT, Baughn LB, Ketterling RP. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. Genes Chromosomes Cancer. 2019 Aug; 58 (8):567-577 Epub 2019 Mar 19
    View PubMed
  81. Peterson JF, Pitel BA, Smoley SA, Smadbeck JB, Johnson SH, Vasmatzis G, Kearney HM, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. Hum Pathol. 2019 Jul; 89:109-114 Epub 2018 Sept 26
    View PubMed
  82. Peterson JF, Blackburn PR, Webley MR, Pearce KE, Williamson CM, Vasmatzis G, Smadbeck JB, Bieliauskas SL, Reichard KK, Ketterling RP, Baughn LB, Greipp PT. Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. Mayo Clin Proc 2019 Jul; 94 (7):1381-1384
    View PubMed
  83. Peterson JF, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Ketterling RP, Macon WR, Baughn LB. Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. Cold Spring Harb Mol Case Stud. 2019 Jun; 5 (3) Epub 2019 June 03
    View PubMed
  84. King RL, McPhail ED, Meyer RG, Vasmatzis G, Pearce K, Smadbeck JB, Ketterling RP, Smoley SA, Greipp PT, Hoppman NL, Peterson JF, Baughn LB. False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. Haematologica 2019 Jun; 104 (6):e248-e251 Epub 2018 Dec 06
    View PubMed
  85. Muppa P, Van DL, Bianco MK, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Sukov WR, Greipp PT, Ketterling RP, Baughn LB, Peterson JF. Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes J Hematopathol. 2019; 12(2):85-90.
  86. Peterson JF, Smoley SA, Luoma IM, Pitel BA, Rice CS, Benevides JC, Vasmatzis G, Smadbeck JB, Yang T, Greipp PT, Ketterling RP, Baughn LB. Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia J Hematopathol. 2019; 12(2):99-104.
  87. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK. Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. Am J Hematol 2019 May; 94 (5):E117-E120 Epub 2019 Feb 06
    View PubMed
  88. Peterson JF, Baughn LB, Ketterling RP, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Mangaonkar AA, Thompson CA, Parikh SA, Chen D, Viswanatha DS. Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv. 2019 Apr 23; 3 (8):1298-1302
    View PubMed
  89. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019 Apr; 94 (4):424-430 Epub 2019 Jan 08
    View PubMed
  90. Harding T, Baughn L, Kumar S, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia. 2019 Apr; 33 (4):863-883 Epub 2019 Jan 25
    View PubMed
  91. Peterson JF, Pitel BA, Smoley SA, Smadbeck JB, Johnson SH, Vasmatzis G, Koon SJ, Webley MR, McGrath M, Bayerl MG, Baughn LB, Rowsey RA, Ketterling RP, Greipp PT, Hoppman NL. Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud. 2019 Apr; 5 (2) Epub 2019 Apr 01
    View PubMed
  92. Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J 2019 Feb 19; 9 (3):20
    View PubMed
  93. Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, Baughn LB, Van Ness B, Rajkumar V, Kumar S, Jen J. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019 Jan 3; 9 (1):2 Epub 2019 Jan 03
    View PubMed
  94. Peterson JF, Pitel BA, Smoley SA, Smadbeck JB, Johnson SH, Vasmatzis G, Pearce KE, He R, Kelemen K, Al-Mondhiry HAB, Lamparella NE, Hoppman NL, Kearney HM, Baughn LB, Ketterling RP, Greipp PT. Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature. Cancer Genet. 2019 Jan; 230:37-46 Epub 2018 Nov 20
    View PubMed
  95. Aypar U, Smoley SA, Pitel BA, Pearce KE, Zenka RM, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Van Dyke DL, Thorland EC, Jenkins RB, Ketterling RP, Greipp PT, Kearney HM, Hoppman NL, Baughn LB. Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. Eur J Haematol. 2019 Jan; 102 (1):87-96 Epub 2018 Nov 22
    View PubMed
  96. Peterson JF, Baughn LB, Pearce KE, Williamson CM, Benevides Demasi JC, Olson RM, Goble TA, Meyer RG, Greipp PT, Ketterling RP. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. Genes Chromosomes Cancer. 2018 Nov; 57 (11):541-546 Epub 2018 Sept 10
    View PubMed
  97. Baughn LB, Pearce K, Larson D, Polley MY, Elhaik E, Baird M, Colby C, Benson J, Li Z, Asmann Y, Therneau T, Cerhan JR, Vachon CM, Stewart AK, Bergsagel PL, Dispenzieri A, Kumar S, Rajkumar SV. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018 Oct 10; 8 (10):96
    View PubMed
  98. Baughn LB, Meredith MM, Baughn LB, Oseth L, Smolarek TA, Hirsch B. SH2B3 aberrations enriched in iAMP21 B lymphoblastic leukemia. Cancer Genet. 2018 Oct; 226-227:30-35 Epub 2018 June 08
    View PubMed
  99. Peterson JF, Van Dyke DL, Hoppman NL, Kearney HM, Sukov WR, Greipp PT, Ketterling RP, Baughn LB. The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. Am J Clin Pathol. 2018 Oct 1; 150 (5):375-384
    View PubMed
  100. Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrozek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Moller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018 Sep; 7 (9):4447-4455 Epub 2018 Aug 16
    View PubMed
  101. Esdal HCD, Ghbeis MB, Saltzman DA, Hess D, Hume JR, Reed RC, Berry SA, Hoggard E, Hirsch B, Baughn LB, Schimmenti LA. Necrotizing Enterocolitis in Two Siblings and an Unrelated Infant with Overlapping Chromosome 6q25 Deletions. Mol Syndromol. 2018 May; 9 (3):141-148 Epub 2018 Apr 28
    View PubMed
  102. Gilles SR, Baughn LB, Schomaker ML, Courville EL, Nelson AC, Sachs Z. Buccal epithelial cells display somatic, bone marrow-derived CALR mutation. Blood Adv. 2017 Nov 28; 1 (25):2302-2306 Epub 2017 Nov 16
    View PubMed
  103. Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, Willemsen MH, Fenckova M, Stumpel CTRM, Bok LA, Sifuentes Saenz M, Byerly KA, Baughn LB, Stegmann APA, Pfundt R, Zhou H, van Bokhoven H, Schenck A, Kramer JM. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder. PLoS Genet. 2017 Oct; 13 (10):e1006864 Epub 2017 Oct 25
    View PubMed
  104. Baughn LB, Sachs Z, Noble-Orcutt KE, Mitra A, Van Ness BG, Linden MA. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leuk Lymphoma. 2017 Aug; 58 (8):1931-1940 Epub 2016 Dec 16
    View PubMed
  105. Baughn LB, Linden MA. Standardization of Minimal Residual Disease Testing in Multiple Myeloma. J Appl Lab Med. 2017 Jul 1; 2 (1):118-122
    View PubMed
  106. Onsongo G, Baughn LB, Bower M, Henzler C, Schomaker M, Silverstein KA, Thyagarajan B. CNV-RF Is a Random Forest-Based Copy Number Variation Detection Method Using Next-Generation Sequencing. J Mol Diagn. 2016 Sep 3;
    View PubMed
  107. Randall N, Courville EL, Baughn L, Afrin L, Ustun C. Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis. American Journal of Hematology.90:(4):E74.
    View PubMed
  108. Nelson AC, Bower M, Baughn LB, Henzler C, Onsongo G, Silverstein KAT, Schomaker M, Deshpande A, Beckman KB, Yohe S, Thyagarajan B. Criteria for clinical reporting of variants from a broad target capture NGS assay without Sanger verification. JSM Biomarkers.2015;2:(1):1005.
  109. Baughn LB, Biegel JA, South ST, Smolarek T, Volkert S, Carroll A, Heerema NA, Rabin KR, Zweidler-McKay PA, Loh M, Hirsch B. Integration of cytogenomic data for furthering the characterization of pediatric B-ALL: a multi-institution, multi-platform microarray study from the Children's Oncology Group (COG). Cancer Genetics.2015;S2210-7762:(14):00247-6.
    View PubMed
  110. Fall D, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden, MA. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. Journal of Cancer.2014;5:(9):720-727.
    View PubMed
  111. Stessman H, Mansoor A, Linden MA, Van Ness B, Baughn LB. Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia and Lymphoma.2014;55:(1):220-2.
    View PubMed
  112. Stessman H, Mansoor A, Janz S, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. Plos One.2013;8:(10):e77608.
    View PubMed
  113. Stessman H, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 2013. 2013; 27(10):2075-7. Epub 2013 May 13.
    View PubMed
  114. Stessman H, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Linden MA, Wu T, Dolloff N, Janz S, Myers C, Van Ness B. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics.2013;12:(6):1140-50.
    View PubMed
  115. Singh C, Yohe S, Baughn LB, Linden MA. Utility of flow cytometry to classify abnormal plasma cell populations in marrow samples collected from patients with putative plasma cell neoplasms. Open Journal of Blood Diseases.2012;2:(3):39-45.
  116. Baughn LB, Kalis SL, MacCarthy T, Wei L, Fan M, Bergman A, Scharff MD. Recombinase mediated cassette exchange as a novel method to study somatic hypermutation in Ramos cells. mBio.2011;2:(5): pii: e00186-11.
    View PubMed
  117. Fessler SP, Rosenberg N, Baughn LB. SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus. Journal of Virology.2011;85:(17):9239-42.
    View PubMed
  118. Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S. CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of Immunology.2009;182:(4):1810-7.
    View PubMed
  119. Baughn LB, Di Liberto, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Research.2006;66:(15):7661-7.
    View PubMed
  120. Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S. Mutually exclusive cdk4-cyclin D1 and cdk6-cyclin D2 pairing inactivates Rb and promotes cell cycle dysregulation in multiple myeloma. Cancer Research.2005;65:(4):11345-53.
    View PubMed
  121. Baughn LB, Rosenberg N. Disruption of the Shc/Grb2 complex during Abelson virus transformation affects proliferation, but not apoptosis. Journal of Virology.2005;79:(4):2325-34.
    View PubMed
  122. Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J. Overexpression, purification, and characterization of the cloned metallobeta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy.1998;42:(4):921-6.
    View PubMed
  123. Crowder MW, Maiti MK, Banovic L, Makaroff CA. Glyoxalase II from A. thaliana requires Zn (II) for catalytic activity. FEBS Letters.1997;418:(3):351-4.
    View PubMed